AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37289583 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP initiation during pregnancy
Number of subjects: 2949
Study 37289583 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP persistence at 9 months postpartum
Number of subjects: 2949
Study 37289583 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adherence to PrEP
Number of subjects: 2949
Study 37289583 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantifiable TFV-DP concentrations
Number of subjects: 2949
Study 37289583 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of PrEP initiation and persistence
Number of subjects: 2949
Study 37289650 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Mindfulness intervention
Number of subjects: 0
Study 37289650 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37289666 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO first line regimens (Group 1-Access)
Number of subjects: 3204
Study 37289666 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO second-line cephalosporins (Group 2-'Low' Watch)
Number of subjects: 3204
Study 37289666 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen providing partial extended-spectrum beta-lactamase (ESBL)/pseudomonal coverage (Group 3-'Medium' Watch)
Number of subjects: 3204
Study 37289666 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbapenem (Group 4-'High' Watch)
Number of subjects: 3204
Study 37289666 — intervention group
Group type: EXPERIMENTAL
Intervention: Reserve antibiotic (Group 5, largely colistin-based)
Number of subjects: 3204
Study 37289666 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial regimens in Groups 1 to 4 escalated to carbapenems
Number of subjects: 3204
Study 37289666 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood culture pathogen positive
Number of subjects: 3204
Study 37289666 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality rate
Number of subjects: 3204
Study 37289666 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality if blood cultures were positive for pathogens
Number of subjects: 3204
Study 37289666 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline NeoSep Severity Score
Number of subjects: 3204
Study 37289666 — intervention group
Group type: EXPERIMENTAL
Intervention: NeoSep Severity Score risk groups
Number of subjects: 3204
Study 37289666 — intervention group
Group type: EXPERIMENTAL
Intervention: NeoSep Recovery Score
Number of subjects: 3204
Study 37289760 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied Relaxation (AR) training
Number of subjects: 277
Study 37289760 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 277
Study 37290035 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus olaparib
Number of subjects: 793
Study 37290035 — intervention group
Group type: COMPARATOR
Intervention: Next-generation hormonal agent (NHA)
Number of subjects: 793
Study 37290035 — intervention group
Group type: COMPARATOR
Intervention: NHA
Number of subjects: 793
Study 37290102 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (2 mg IV)
Number of subjects: 164
Study 37290102 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 mL normal saline IV)
Number of subjects: 164
Study 37290104 — intervention group
Group type: EXPERIMENTAL
Intervention: RRSO (Risk-Reducing Salpingo-Oophorectomy)
Number of subjects: 100
Study 37290104 — intervention group
Group type: COMPARATOR
Intervention: Non-RRSO (Ovarian Conservation)
Number of subjects: 100
Study 37290104 — intervention group
Group type: EXPERIMENTAL
Intervention: RRSO with hormone use
Number of subjects: 100
Study 37290104 — intervention group
Group type: EXPERIMENTAL
Intervention: RRSO without hormone use
Number of subjects: 100
Study 37290106 — intervention group
Group type: EXPERIMENTAL
Intervention: Labor induction at 39 weeks of gestation
Number of subjects: 6058
Study 37290346 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed Consent (IC) risk of harm statement for dry needling
Number of subjects: 5
Study 37290461 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus cabozantinib (1200 mg intravenously every 3 weeks + 60 mg orally once daily)
Number of subjects: 522
Study 37290461 — intervention group
Group type: COMPARATOR
Intervention: Cabozantinib (60 mg orally once daily)
Number of subjects: 522
Study 37290461 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus cabozantinib
Number of subjects: 522
Study 37290461 — intervention group
Group type: COMPARATOR
Intervention: Cabozantinib
Number of subjects: 522
Study 37290468 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-gemcitabine
Number of subjects: 240
Study 37290468 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-fluorouracil
Number of subjects: 240
Study 37290591 — intervention group
Group type: EXPERIMENTAL
Intervention: VIR-2218 (200 mg)
Number of subjects: 24
Study 37290591 — intervention group
Group type: EXPERIMENTAL
Intervention: ALN-HBV
Number of subjects: 24
Study 37290591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 37290591 — intervention group
Group type: EXPERIMENTAL
Intervention: VIR-2218
Number of subjects: 24
Study 37290730 — intervention group
Group type: EXPERIMENTAL
Intervention: e-PROs (electronic patient-reported outcomes)
Number of subjects: 154
Study 37290740 — intervention group
Group type: EXPERIMENTAL
Intervention: Total energy expenditure (TEE) assessed by 24-h whole-room indirect calorimeter
Number of subjects: 31
Study 37290740 — intervention group
Group type: COMPARATOR
Intervention: Cancer-specific predicted energy requirements (25-30 kcal/kg)
Number of subjects: 31
Study 37290822 — intervention group
Group type: EXPERIMENTAL
Intervention: DMEK
Number of subjects: 72
Study 37290822 — intervention group
Group type: COMPARATOR
Intervention: Control (phacoemulsification and lens implantation)
Number of subjects: 72
Study 37290822 — intervention group
Group type: EXPERIMENTAL
Intervention: UT-DSAEK
Number of subjects: 72
Study 37290823 — intervention group
Group type: EXPERIMENTAL
Intervention: Tessellated fundus
Number of subjects: 579
Study 37290823 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse chorioretinal atrophy
Number of subjects: 579
Study 37290823 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal macular ChT
Number of subjects: 579
Study 37290915 — intervention group
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA PET/CT imaging
Number of subjects: 100
Study 37290915 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate bed salvage radiotherapy (SRT)
Number of subjects: 100
Study 37290915 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 100
Study 37290915 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 100
Study 37290915 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation
Number of subjects: 100
Study 37290915 — intervention group
Group type: EXPERIMENTAL
Intervention: NCCN high-risk features, stage > pT3 and ISUP score > 3
Number of subjects: 100
Study 37290915 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartiles of PSA
Number of subjects: 100
Study 37290947 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision rule (Marburg Heart Score combined with hs-cTnI-POCT, limit of detection 1.6 ng/L, cut-off value 3.8 ng/L)
Number of subjects: 1500
Study 37290947 — intervention group
Group type: COMPARATOR
Intervention: Regular care (control group)
Number of subjects: 1500
Study 37290945 — intervention group
Group type: EXPERIMENTAL
Intervention: Pour-flush toilet and septic tank intervention
Number of subjects: 400
Study 37290945 — intervention group
Group type: COMPARATOR
Intervention: Control sites (original criteria)
Number of subjects: 400
Study 37290967 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab de-escalation (various regimens including discontinuations and switches to oral treatment)
Number of subjects: 137
Study 37290996 — intervention group
Group type: EXPERIMENTAL
Intervention: INCB053914 (monotherapy)
Number of subjects: 97
Study 37290996 — intervention group
Group type: EXPERIMENTAL
Intervention: INCB053914 + cytarabine (AML)
Number of subjects: 97
Study 37290996 — intervention group
Group type: EXPERIMENTAL
Intervention: INCB053914 + azacitidine (AML)
Number of subjects: 97
Study 37290996 — intervention group
Group type: EXPERIMENTAL
Intervention: INCB053914 + ruxolitinib (MF)
Number of subjects: 97
Study 37291118 — intervention group
Group type: EXPERIMENTAL
Intervention: KSHV DNA seropositivity in DCM patients
Number of subjects: 696
Study 37291118 — intervention group
Group type: EXPERIMENTAL
Intervention: KSHV DNA load in plasma
Number of subjects: 696
Study 37291118 — intervention group
Group type: EXPERIMENTAL
Intervention: KSHV DNA seropositivity and cardiovascular outcomes
Number of subjects: 696
Study 37291118 — intervention group
Group type: EXPERIMENTAL
Intervention: KSHV DNA load in heart tissues
Number of subjects: 696
Study 37291210 — intervention group
Group type: EXPERIMENTAL
Intervention: Trofinetide
Number of subjects: 93
Study 37291210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 37291212 — intervention group
Group type: EXPERIMENTAL
Intervention: AEF0117, a signaling-specific inhibitor of the cannabinoid receptor 1 (CB1)
Number of subjects: 0
Study 37291428 — intervention group
Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE) scoring system
Number of subjects: 43
Study 37291428 — intervention group
Group type: COMPARATOR
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 43
Study 37291428 — intervention group
Group type: EXPERIMENTAL
Intervention: pCLE diagnostic scoring
Number of subjects: 43
Study 37291428 — intervention group
Group type: EXPERIMENTAL
Intervention: Local regrowth detection
Number of subjects: 43
Study 37291448 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant medication that inhibits or induces CYP3A4, TSPO genetic status, age, BMI, and sex
Number of subjects: 0
Study 37291541 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse Trendelenburg position with positive pressure ventilation (RT/PPV)
Number of subjects: 50
Study 37291541 — intervention group
Group type: COMPARATOR
Intervention: Ramp position with zero end-expiratory pressure (RP/ZEEP)
Number of subjects: 50
Study 37291543 — intervention group
Group type: EXPERIMENTAL
Intervention: Child in Context Intervention (CICI) - individualized, goal-oriented, home-based tele-rehabilitation intervention comprising seven tele-rehabilitation sessions, one in-person parent seminar, and four digital school meetings over a 4- to 5-month period.
Number of subjects: 23
Study 37291543 — intervention group
Group type: EXPERIMENTAL
Intervention: Child in Context Intervention (CICI) - psychoeducation about targeted acquired brain injury-related problems.
Number of subjects: 23
Study 37291599 — intervention group
Group type: EXPERIMENTAL
Intervention: tCBT + TAU
Number of subjects: 231
Study 37291599 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 231
Study 37291651 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg/h continuous infusion after initial loading doses of 0.5 μg/kg for 15 min
Number of subjects: 60
Study 37291651 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.75 μg/kg/h continuous infusion after initial loading doses of 0.75 μg/kg for 15 min
Number of subjects: 60
Study 37291651 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg/h continuous infusion
Number of subjects: 60
Study 37291651 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.75 μg/kg/h continuous infusion
Number of subjects: 60
Study 37291651 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.03 mg/kg at anaesthesia induction
Number of subjects: 60
Study 37291651 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (NS)
Number of subjects: 60
Study 37291651 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60
Study 37291651 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg
Number of subjects: 60
Study 37291651 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.75 μg/kg
Number of subjects: 60
Study 37291677 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg IV imatinib twice daily for a maximum of seven days
Number of subjects: 66
Study 37291677 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg IV imatinib twice daily for a maximum of seven days in a subgroup of patients with high IL-6, TNFR1 and SP-D levels (n=20)
Number of subjects: 66
Study 37291679 — intervention group
Group type: COMPARATOR
Intervention: Post-acute COVID-19 in ARD patients (≥ 4 weeks)
Number of subjects: 108
Study 37291679 — intervention group
Group type: COMPARATOR
Intervention: Post-acute COVID-19 in non-ARD controls (≥ 4 weeks)
Number of subjects: 108
Study 37291679 — intervention group
Group type: COMPARATOR
Intervention: Post-acute COVID-19 in ARD patients (> 12 weeks)
Number of subjects: 108
Study 37291679 — intervention group
Group type: COMPARATOR
Intervention: Post-acute COVID-19 in non-ARD controls (> 12 weeks)
Number of subjects: 108
Study 37291679 — intervention group
Group type: COMPARATOR
Intervention: ≥ 3 symptoms in ARD patients (≥ 4 weeks)
Number of subjects: 108
Study 37291679 — intervention group
Group type: COMPARATOR
Intervention: ≥ 3 symptoms in non-ARD controls (≥ 4 weeks)
Number of subjects: 108
Study 37291679 — intervention group
Group type: COMPARATOR
Intervention: ≥ 3 symptoms in ARD patients (> 12 weeks)
Number of subjects: 108
Study 37291679 — intervention group
Group type: COMPARATOR
Intervention: ≥ 3 symptoms in non-ARD controls (> 12 weeks)
Number of subjects: 108
Study 37291721 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance spectroscopy measurements (phase angle, fat mass, fat-free mass)
Number of subjects: 60
Study 37291721 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase angle improvement in the first month postoperatively
Number of subjects: 60
Study 37291721 — intervention group
Group type: EXPERIMENTAL
Intervention: Low perioperative and 1-mo phase angles
Number of subjects: 60
Study 37291722 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD (Chronic Kidney Disease)
Number of subjects: 0
Study 37291731 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of propofol (1.4 mg/kg TBW)
Number of subjects: 68
Study 37291731 — intervention group
Group type: COMPARATOR
Intervention: High dose of propofol (2.7 mg/kg TBW)
Number of subjects: 68
Study 37291963 — intervention group
Group type: EXPERIMENTAL
Intervention: eNET intervention (10-12 sessions via videoconference)
Number of subjects: 21
Study 37291968 — intervention group
Group type: EXPERIMENTAL
Intervention: Low phytic acid pea supplementation
Number of subjects: 0
Study 37291968 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37292376 — intervention group
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (T-VEC) delivered by intralesional injection at 10
Number of subjects: 15
Study 37292588 — intervention group
Group type: EXPERIMENTAL
Intervention: Training intervention for sustainability capacity building
Number of subjects: 23
Study 37292588 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training intervention)
Number of subjects: 23
Study 37292588 — intervention group
Group type: EXPERIMENTAL
Intervention: CDC-recommended funding and American Lung Association smoke-free scores (proxy for policy environment)
Number of subjects: 23
Study 37292667 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated OSA symptom subtypes
Number of subjects: 2643
Study 37292667 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline age
Number of subjects: 2643
Study 37292667 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline BMI
Number of subjects: 2643
Study 37292667 — intervention group
Group type: EXPERIMENTAL
Intervention: Being female
Number of subjects: 2643
Study 37292667 — intervention group
Group type: EXPERIMENTAL
Intervention: AHI (Apnea-Hypopnea Index)
Number of subjects: 2643
Study 37292711 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccine
Number of subjects: 0
Study 37292774 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Blood Pressure Reduction (MB-BP) program
Number of subjects: 201
Study 37292774 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care control
Number of subjects: 201
Study 37292800 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive protein hydrolysate formulas (EHF)
Number of subjects: 0
Study 37292800 — intervention group
Group type: COMPARATOR
Intervention: Cow milk formula (CMF)
Number of subjects: 0
Study 37292800 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formula types
Number of subjects: 0
Study 37292982 — intervention group
Group type: EXPERIMENTAL
Intervention: High-cash gift ($333 per month, or $3,996 per year)
Number of subjects: 1000
Study 37292982 — intervention group
Group type: COMPARATOR
Intervention: Low-cash gift (amount not specified)
Number of subjects: 1000
Study 37293030 — intervention group
Group type: EXPERIMENTAL
Intervention: d-serine + AudRem (100 mg/kg)
Number of subjects: 21
Study 37293030 — intervention group
Group type: COMPARATOR
Intervention: AudRem
Number of subjects: 21
Study 37293067 — intervention group
Group type: EXPERIMENTAL
Intervention: Powder-based product (potato maltodextrin) mixed with expressed breast milk, administered daily for 4 weeks
Number of subjects: 10
Study 37293139 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-directed medical therapy (co-GDMT) as per European Society of Cardiology guidelines
Number of subjects: 0
Study 37293139 — intervention group
Group type: COMPARATOR
Intervention: No specific control intervention mentioned
Number of subjects: 0
Study 37293235 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic biofilm
Number of subjects: 10
Study 37293235 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium alginate biofilm
Number of subjects: 10
Study 37293235 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 10
Study 37293235 — intervention group
Group type: COMPARATOR
Intervention: Unstimulated salivary flow
Number of subjects: 10
Study 37293434 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized THC/CBD 1:2 oil extract
Number of subjects: 24
Study 37293434 — intervention group
Group type: COMPARATOR
Intervention: Hemp seed oil (placebo)
Number of subjects: 24
Study 37293631 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated package of HIV and sexual and reproductive health services including family planning
Number of subjects: 0
Study 37293631 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider experiences and perspectives
Number of subjects: 0
Study 37294085 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus pembrolizumab
Number of subjects: 213
Study 37294085 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 213
Study 37294089 — intervention group
Group type: EXPERIMENTAL
Intervention: Nudge intervention (automated reminder message for clinicians)
Number of subjects: 222
Study 37294089 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 222
Study 37294101 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based sexual counseling (4-week, 8-session program)
Number of subjects: 134
Study 37294101 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 134
Study 37294145 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Electrolytes Solution (MES) (n = 351)
Number of subjects: 708
Study 37294145 — intervention group
Group type: COMPARATOR
Intervention: 0.9% Saline (n = 357)
Number of subjects: 708
Study 37294145 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Electrolytes Solution (MES)
Number of subjects: 708
Study 37294145 — intervention group
Group type: COMPARATOR
Intervention: 0.9% Saline
Number of subjects: 708
Study 37294245 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide (glucagon-like peptide-1 receptor agonist)
Number of subjects: 1146
Study 37294245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1146
Study 37294342 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus doxorubicin every 3 weeks for 6 cycles followed by pembrolizumab maintenance until disease progression or intolerance.
Number of subjects: 10
Study 37294433 — intervention group
Group type: EXPERIMENTAL
Intervention: faricimab 6.0 mg Q16W
Number of subjects: 120
Study 37294433 — intervention group
Group type: COMPARATOR
Intervention: aflibercept 2.0 mg Q8W
Number of subjects: 120
Study 37294458 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary MPS patients
Number of subjects: 45
Study 37294458 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary MPS patients with BDI score ≥ 17
Number of subjects: 45
Study 37294477 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ibuprofen 10 mg/kg every 6 hours, up to four doses per day
Number of subjects: 24
Study 37294477 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ibuprofen
Number of subjects: 24
Study 37294569 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer reviewers received an email to check 10 CONSORT items
Number of subjects: 510
Study 37294569 — intervention group
Group type: COMPARATOR
Intervention: Usual journal practice (control group)
Number of subjects: 510
Study 37294569 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer reviewers received an email to check 10 SPIRIT items
Number of subjects: 510
Study 37294571 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained public health interventions including increased MOUD initiation by 2- or 5-fold, improved MOUD retention, increased naloxone distribution, and safe opioid prescribing.
Number of subjects: 4
Study 37294571 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained public health interventions for an additional 3 years.
Number of subjects: 4
Study 37294588 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health platform for home hospitalization (HH)
Number of subjects: 63
Study 37294604 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted interactive obesity treatment approach for 6 months
Number of subjects: 52
Study 37294604 — intervention group
Group type: COMPARATOR
Intervention: Attentional control condition for 6 months
Number of subjects: 52
Study 37294609 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion intervention via a web-based community game (Habbo; Sulake Oy)
Number of subjects: 22
Study 37294609 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of 27 recommendations for intervention preparation and implementation in web-based games
Number of subjects: 22